Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07468630) titled 'Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma' on March 9.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Condition:
Colon Adenocarcinoma
Intervention:
Drug: Tolecizumab (PCSK9 Inhibitor)
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: April 10, 2026
Target Sample Size: 106
Countries of Recruitment:
China
To know ...